Do High Blood Pressure Meds Reduce the Risk of ALS?
People who took prescription medications for hypertension were less likely than others to develop amyotrophic lateral sclerosis.
6400 RESULTS
Sort By:
People who took prescription medications for hypertension were less likely than others to develop amyotrophic lateral sclerosis.
Basic preclinical discoveries keep meeting vibrant for neurodegenerative disease researchers from around the world
A micro-immunoelectrode allows researchers measure Aβ levels in the interstitial fluid of mice every 30 seconds.
A study in a mouse model of Alzheimer’s disease proposes that degenerating neurons become more excitable because they lose dendrites.
Having variants in three, or even two, genes for amyotrophic lateral sclerosis brings on symptoms a decade earlier. This also happens in sporadic cases, bringing the very term into question, researchers say.
High doses of BACE1 inhibitors stymie synaptic activity in mice. Researchers recommend careful dosing in clinical trials.
Protein touted as a peripheral monocyte receptor that worsens amyloid plaque pathology in transgenic mice.
Medication blocks molecular transporters that eject riluzole from the nervous system.
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
The amino terminus toggles between a neatly folded nucleic acid-binding domain and a disorganized configuration that forms inclusions.
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
At CTAD, former FDA neurology leader Rusty Katz urged Alzheimer’s trialists to stop fussing over disease progression. He recommended going after a large effect, regardless of whether it can garner a label of disease modification. That, he says, may mean combination trials.
No filters selected